Therapeutic and diagnostic products

Femasys has achieved global regulatory approvals for a first-line infertility treatment and complimentary diagnostic products.


Infertility has become a significant global problem, which may be the result of limited advancements over the last 30 years.

More than 10 million women contend with infertility in the U.S.1
Causes of Infertility…
A blue box containing a female icon indicating that one third of infertility cases are due to female only factors.
A blue box containing male and female icons indicating that one third of infertility cases are caused by joint female and male factors.
Blue square containing a male icon indicating the one third of infertility is from male factor only.
~40-50% is due to male factor.2 Sperm counts worldwide have declined by >50%.3
  1. Kumar N, et al. (2015) Trends of male factor infertility, an important cause of infertility: A review of literature. J Hum Reprod Sci. 8(4): 191–196. doi: 10.4103/0974-1208.170370:
  2. Levine H, et al. (2023) Temporal trends in sperm count: a systematic review and meta-regression analysis of samples collected globally in the 20th and 21st centuries. Human Reproduction Update, Vol.29, No.2, pp. 157–176, 2023

Our Infertility Portfolio

FemaSeed logo

FemaSeed is the latest in artificial insemination technology, engineered to precisely deliver sperm into the fallopian tube, the site of conception, to enhance natural fertilization.  As a highly cost-effective approach that carries notably reduced risks compared to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), FemaSeed is positioned as a first-line therapeutic option. 

FemaSeed has regulatory approvals in the U.S. and Canada.

Mechanism of action showing FemaSeed Intratubal Insemination.
FemVue Logo

FemVue is the first FDA-cleared product that creates natural saline and air contrast and enables safe, reliable, and real time evaluation of the fallopian tubes with ultrasound. When performed with a uterine cavity assessment, a more comprehensive exam can be achieved from the comfort of the GYN’s office.

FemVue has regulatory approvals in the U.S., Japan, and Canada.

FemCath Logo

FemCath, an FDA-cleared intrauterine catheter, is the first to allow for selective evaluation of a fallopian tube with contrast. FemCath features our proprietary delivery platform, which places balloon technology close to the opening of a selected fallopian tube for directed delivery.

FemCath has regulatory approvals in the U.S. and Canada.

How it works
Mechanism of action showing FemVue with FemCath.